Ecuador Medical Device Definition: Types, Registration Duty and Exemptions

1. Key takeaways

Ecuador applies a dual division to medical devices combining risk class and device type: four risk classes, I/II/III/IV, and four device types, DMA (active), DMI (invasive), DMNI (non-invasive) and DMDIV (in vitro diagnostic). Article 5 requires a health registration for manufacturing, import, distribution, commercialization and sale; Article 29 lists 5 categories of registration exemptions, including custom-made devices, devices used for research purposes, and parts and components that form an integral part of a device.

2. Legal basis

Exemptions listed in Article 29, following the original enumeration: (a) custom-made (personalized) devices; (b) devices used in a scientific setting for research purposes and not intended for commercialization; (c) accessories, components, parts and spare parts that form an integral part of a device, are exclusively dedicated to its established intended purpose and are stated in the instructions for use, covered by the registration certificate of the device into which they are incorporated, provided they are not commercialized separately and have no independent intended purpose; (d) software that controls or drives hardware devices and has no medical purpose of its own, or that forms an integral part of the operation of such a device; (e) devices that have been refurbished or remanufactured.

3. Expert insights

Insight one: exemption from registration is not exemption from oversight, and the conditions of Article 29 (c) are threefold. To benefit from the exemption, accessories, components, parts and spare parts must simultaneously form an integral part of the device, be exclusively dedicated to its established intended purpose, and be stated in the instructions for use or the user manual; in addition there is one negative condition, that they are not commercialized separately and have no independent intended purpose. This is the most common misjudgment among OEM manufacturers: as soon as a part is sold separately, or the manufacturer assigns it an independent intended purpose, the exemption is lost.

Insight two: item (b) echoes the RUO definition. Article 3 defines RUO (Research Use Only) products, and Article 29 (b) exempts devices used for research purposes. Read together, research-dedicated use is a lawful but strictly bounded channel: any move toward commercialization triggers registration.

Insight three: item (d) draws the dividing line for software, and it works in tandem with Article 22. Software that controls or drives hardware and has no medical purpose of its own is exempt; standalone commercialized SaMD must be classified under the IMDRF/N12 matrix and registered (Article 22, item e); software used in combination with another device automatically takes the class of the host device and its registration certificate (Article 22, item d). The decisive criteria are whether there is an independent medical purpose and whether there is separate commercialization, not the technical form.

Insight four: item (e) places refurbished and remanufactured devices outside the registration system. Devices that have been modified or remanufactured (repotenciados o remanufacturados, meaning devices whose original manufacture has been altered by a process) are exempt from registration. This does not mean they can be sold freely: their circulation remains subject to other rules, and the red lines of Article 30 apply equally.

Insight five: Article 30 sets two absolute refusal red lines. (a) devices containing ingredients prohibited nationally or internationally, as published in the ARCSA list; (b) devices subject to health alerts (alertas sanitarias). These are screening items that manufacturers in the Chinese mainland should clear at the formulation and material design stage, long before submission.

Insight six: the five verbs of Article 5 cover the whole lifecycle. Manufacturing, import, distribution, commercialization and sale: a missing certificate at any single step is a violation, and the obligation is not limited to the import stage.

4. Practical recommendations

1. Before exporting parts and components, determine whether they will be commercialized separately: separate sale means an independent registration is required.
2. For software products, first determine whether there is an independent medical purpose, and on that basis separate exempt software, embedded software and standalone SaMD.
3. Retain research-purpose evidence for RUO exports to guard against later commercialization disputes.
4. Screen the prohibited ingredient lists at the formulation and material design stage, avoiding outright refusal under Article 30 at the review stage.
5. Tag each model in the product ledger with its device type code (DMA/DMI/DMNI/DMDIV) to simplify later classification and dossier assembly.

5. Verification checklist

• □ Each model has been tagged with its device type (DMA/DMI/DMNI/DMDIV)
• □ Parts and components have been assessed against the three positive conditions and one negative condition of Article 29 (c)
• □ The independent medical purpose of software products has been determined, separating exempt software, embedded software and SaMD
• □ Products have been screened against national and international prohibited ingredient lists
• □ Products have been confirmed free of standing health alert records
• □ Research-purpose evidence for RUO exports has been confirmed complete

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation